How can survival be improved in localized osteosarcoma?

Expert Review of Anticancer Therapy

Volumn 10, Issue 8, 2010, Pages 1313-1325

  Jeon, Dae Geun ^a   Song, Won Seok ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

chemotherapy; osteosarcoma; prognostic factor; treatment strategy

Indexed keywords

ALKALINE PHOSPHATASE; BLEOMYCIN; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EZRIN; GELATINASE A; GELATINASE B; GEMCITABINE; HISTONE DEACETYLASE 1; IFOSFAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MURAMYL TRIPEPTIDE; PEGINTERFERON ALPHA; PHOSPHATIDYLETHANOLAMINE; RAPAMYCIN; UROKINASE; VALPROIC ACID; VASCULOTROPIN; VINCRISTINE;

AGE; ANTIANGIOGENIC THERAPY; BONE RESECTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SIZE; CANCER SURVIVAL; DELAYED DIAGNOSIS; DRUG MEGADOSE; HUMAN; OSTEOSARCOMA; OUTCOME ASSESSMENT; PATHOLOGIC FRACTURE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; REVIEW; TREATMENT PLANNING;

EID: 77956242672     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.79     Document Type: Review

References (122)

1. Rosenburg SA, Chabner BA, Young RC et al. Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat. Rep. 63(5), 739-751 (1979).
2. Campanacci M, Bacci G, Bertoni F et al. The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli. Cancer 48(7), 1569-1581 (1981).
3. Rosen G, Marcove RC, Caparros B et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43(6), 2163-2177 (1979).
4. Rosen G, Tan C, Sanmaneechai A et al. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer 35(3 Suppl.), 936-945 (1975).
5. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63(11-12), 1727-1733 (1979).
6. DeVita VT Jr. Progress in cancer management. Keynote address. Cancer 51(12 Suppl.), 2401-2409 (1983).
7. Malawer MM, Link MP, Donaldson SS. Sarcoma of bone: chemotherapy for bone sarcomas. In: Cancer: Principle and Practice of Oncology. DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Lippincott-Raven, PA, USA 1804-1811 (1997).
8. Goorin AM, Schwartzentruber DJ, Devidas M et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J. Clin. Oncol. 21(8), 1574-1580 (2003).
9. Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 20(3), 776-790 (2002).
10. Meyers PA, Heller G, Healey J et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan- Kettering experience. J. Clin. Oncol. 10(1), 5-15 (1992).
11. Rosen G, Caparros B, Huvos AG et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49(6), 1221-1230 (1982).
12. Bacci G, Picci P, Ferrari S et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72(11), 3227-3238 (1993).
13. Provisor AJ, Ettinger LJ, Nachman JB et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J. Clin. Oncol. 15(1), 76-84 (1997).
14. Winkler K, Beron G, Delling G et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J. Clin. Oncol. 6(2), 329-337 (1988).
15. Saeter G, Alvegard TA, Elomaa I et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J. Clin. Oncol. 9(10), 1766-1775 (1991).
16. Meyers PA, Gorlick R, Heller G et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J. Clin. Oncol. 16(7), 2452-2458 (1998).
17. Smeland S, Muller C, Alvegard TA et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur. J. Cancer 39(4), 488-494 (2003).
18. Souhami RL, Craft AW, Van der Eijken JW et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350(9082), 911-917 (1997).
19. Eselgrim M, Grunert H, Kuhne T et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr. Blood Cancer 47(1), 42-50 (2006).
20. Le Deley MC, Guinebretiere JM, Gentet JC et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur. J. Cancer 43(4), 752-761 (2007).
21. Fuchs N, Bielack SS, Epler D et al. Long-term results of the co-operative German-Austrian-Swiss Osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann. Oncol. 9(8), 893-899 (1998).
22. Bacci G, Ferrari S, Longhi A et al. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/ Scandinavian Sarcoma Group pilot study. J. Chemother. 14(2), 198-206 (2002).
23. Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J. Clin. Oncol. 23(34), 8845-8852 (2005).
24. Meyers PA, Schwartz CL, Krailo MD et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J. Clin. Oncol. 26(4), 633-638 (2008).
25. Leu KM, Ostruszka LJ, Shewach D et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J. Clin. Oncol. 22(9), 1706-1712 (2004).
26. Navid F, Willert JR, McCarville MB et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113(2), 419-425 (2008).
27. Anderson PM, Wiseman GA, Erlandson L et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin. Cancer Res. 11(19 Pt 1), 6895-6900 (2005).
28. O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev. Anticancer Ther. 9(4), 511-523 (2009).
29. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev. Anticancer Ther. 6(7), 1075-1085 (2006).
30. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (DOXIL) in sarcoma. Cancer Invest. 21(2), 167-176 (2003).
31. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat. Res. 152, 239-262 (2010).
32. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat. Rev. Cancer 3(9), 685-694 (2003).
33. Maloney EK, McLaughlin JL, Dagdigian NE et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63(16), 5073-5083 (2003).
34. Kolb EA, Gorlick R, Houghton PJ et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr. Blood Cancer 50(6), 1190-1197 (2008).
35. Scotlandi K, Manara MC, Nicoletti G et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65(9), 3868-3876 (2005).
36. Lopaczynski W, Terry C. Insulin-like growth factor I activates insulin receptor substrate 1 and Ras in human osteosarcoma cells. Acta Biochim. Pol. 46(1), 117-123 (1999).
37. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 65(6), 2406-2411 (2005).
38. Houghton PJ, Morton CL, Kolb EA et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer 50(4), 799-805 (2008).
39. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin. Cancer Res. 14(10), 2962-2969 (2008).
40. Kaya M, Wada T, Akatsuka T et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin. Cancer Res. 6(2), 572-577 (2000).
41. Kaya M, Wada T, Kawaguchi S et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br. J. Cancer 86(6), 864-869 (2002).
42. Wittenburg LA, Bisson L, Rose BJ, Korch C, Thamm DH. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother. Pharmacol. DOI: 10.1007/s00280-010-1287-z (2010) (Epub ahead of print).
43. Hudson M, Jaffe MR, Jaffe N et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J. Clin. Oncol. 8(12), 1988-1997 (1990).
44. Bacci G, Longhi A, Bertoni F et al. Primary high-grade osteosarcoma: comparison between preadolescent and older patients. J. Pediatr. Hematol. Oncol. 27(3), 129-134 (2005).
45. Ferrari S, Bertoni F, Mercuri M et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann. Oncol. 12(8), 1145-1150 (2001).
46. Lee JA, Kim MS, Kim DH et al. Osteosarcoma developed in the period of maximal growth rate have inferior prognosis. J. Pediatr. Hematol. Oncol. 30(6), 419-424 (2008).
47. Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin. Orthop. Relat. Res. (397), 53-61 (2002).
48. Jeon DG, Lee SY, Cho WH, Song WS, Park JH. Primary osteosarcoma in patients older than 40 years of age. J. Korean Med. Sci. 21(4), 715-718 (2006).
49. Bacci G, Ferrari S, Mercuri M et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop. 78(3), 377-384 (2007).
50. Harting MT, Lally KP, Andrassy RJ et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J. Cancer Res. Clin. Oncol. 136(4), 561-570 (2010).
51. Song WS, Kong CB, Jeon DG et al. Prognosis of extremity osteosarcoma in patients aged 40-60 years: a cohort/case controlled study at a single institute. Eur. J. Surg. Oncol. 36(5), 483-488 (2010).
52. Kawai A, Huvos AG, Meyers PA, Healey JH. Osteosarcoma of the pelvis. Oncologic results of 40 patients. Clin. Orthop. Relat. Res. 348, 196-207 (1998).
53. Ozaki T, Flege S, Kevric M et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J. Clin. Oncol. 21(2), 334-341 (2003).
54. Daecke W, Bielack S, Martini AK et al. Osteosarcoma of the hand and forearm: experience of the Cooperative Osteosarcoma Study Group. Ann. Surg. Oncol. 12(4), 322-331 (2005).
55. Bramer JA, van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur. J. Surg. Oncol. 35(10), 1030-1036 (2009).
56. Cho WH, Song WS, Jeon DG et al. Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations. Ann. Surg. Oncol. 17(3), 702-708 (2010).
57. Haworth JM, Watt I, Park WM, Roylance J. Diaphyseal osteosarcoma. Br. J. Radiol. 54(647), 932-938 (1981).
58. Sim FH, Frassica FJ, Unni KK. Osteosarcoma of the diaphysis of long bones: clinicopathologic features and treatment of 51 cases. Orthopedics 18(1), 19-23 (1995).
59. Kong CB, Kim MS, Lee SY et al. Prognostic effect of diaphyseal location in osteosarcoma: a cohort case-control study at a single institute. Ann. Surg. Oncol. 16(11), 3094-3100 (2009).
60. Bieling P, Rehan N, Winkler P et al. Tumor size and prognosis in aggressively treated osteosarcoma. J. Clin. Oncol. 14(3), 848-858 (1996).
61. Kim MS, Lee SY, Cho WH et al. An examination of the efficacy of the 8 cm maximal tumor diameter cutoff for the subdivision of AJCC stage II osteosarcoma patients. J. Surg. Oncol. 98(6), 427-431 (2008).
62. Bacci G, Longhi A, Versari M et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106(5), 1154-1161 (2006).
63. Lindner NJ, Ramm O, Hillmann A et al. Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin. Orthop. Relat. Res. (358), 83-89 (1999).
64. Kim MS, Lee SY, Cho WH et al. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. J. Surg. Oncol. 97(5), 456-461 (2008).
65. Jaffe N, Spears R, Eftekhari F et al. Pathologic fracture in osteosarcoma. Impact of chemotherapy on primary tumor and survival. Cancer 59(4), 701-709 (1987).
66. Bramer JA, Abudu AA, Grimer RJ, Carter SR, Tillman RM. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur. J. Cancer 43(13), 1944-1951 (2007).
67. Bacci G, Ferrari S, Longhi A et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop. Scand. 74(4), 449-454 (2003).
68. Kim MS, Lee SY, Lee TR et al. Prognostic effect of pathologic fracture in localized osteosarcoma: a cohort/case controlled study at a single institute. J. Surg. Oncol. 100(3), 233-239 (2009).
69. Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications. J. Bone Joint Surg. Am. 84-A(1), 49-57 (2002).
70. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur. J. Cancer 38(9), 1218-1225 (2002).
71. Bacci G, Bertoni F, Longhi A et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 97(12), 3068-3075 (2003).
72. Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. Time dependency of prognostic factors in patients with stage II osteosarcomas. Clin. Orthop. Relat. Res. 463, 157-165 (2007).
73. Hauben EI, Bielack S, Grimer R et al. Clinico-histologic parameters of osteosarcoma patients with late relapse. Eur. J. Cancer 42(4), 460-466 (2006).
74. Brouns F, Stas M, De Wever I. Delay in diagnosis of soft tissue sarcomas. Eur. J. Surg. Oncol. 29(5), 440-445 (2003).
75. Clark MA, Thomas JM. Delay in referral to a specialist soft-tissue sarcoma unit. Eur. J. Surg. Oncol. 31(4), 443-448 (2005).
76. Rougraff BT, Davis K, Lawrence J. Does length of symptoms before diagnosis of sarcoma affect patient survival? Clin. Orthop. Relat. Res. 462, 181-189 (2007).
77. Saithna A, Pynsent PB, Grimer RJ. Retrospective analysis of the impact of symptom duration on prognosis in soft tissue sarcoma. Int. Orthop. 32(3), 381-384 (2008).
78. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J. Bone Joint Surg. Am. 82(5), 667-674 (2000).
79. Ayerza MA, Muscolo DL, Aponte- Tinao LA, Farfalli G. Effect of erroneous surgical procedures on recurrence and survival rates for patients with osteosarcoma. Clin. Orthop. Relat. Res. 452, 231-235 (2006).
80. Kim MS, Lee SY, Cho WH et al. Prognostic effect of inadvertent curettage without treatment delay in osteosarcoma. J. Surg. Oncol. 100(6), 484-487 (2009).
81. Kim MS, Lee SY, Cho WH et al. Prognostic effects of doctor-associated diagnostic delays in osteosarcoma. Arch. Orthop. Trauma Surg. 129(10), 1421-1425 (2009).
82. Bacci G, Picci P, Ferrari S et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 71(4), 1224-1230 (1993).
83. Bacci G, Longhi A, Ferrari S et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol. Rep. 9(1), 171-175 (2002).
84. Foukas AF, Deshmukh NS, Grimer RJ et al. Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J. Bone Joint Surg. Br. 84(5), 706-711 (2002).
85. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J. Cancer Res. Clin. Oncol. 134(3), 281-297 (2008).
86. Laverdiere C, Hoang BH, Yang R et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin. Cancer Res. 11(7), 2561-2567 (2005).
87. Khanna C, Wan X, Bose S et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10(2), 182-186 (2004).
88. Ferrari S, Zanella L, Alberghini M et al. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. 50(4), 752-756 (2008).
89. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J. Clin. Oncol. 12(2), 423-431 (1994).
90. Bacci G, Mercuri M, Longhi A et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur. J. Cancer 41(14), 2079-2085 (2005).
91. Salzer-Kuntschik M, Brand G, Delling G. [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors]. Pathologe 4(3), 135-141 (1983).
92. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch. Pathol. Lab. Med. 101(1), 14-18 (1977).
93. Picci P, Bacci G, Campanacci M et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 56(7), 1515-1521 (1985).
94. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205-216 (2000).
95. Onikul E, Fletcher BD, Parham DM, Chen G. Accuracy of MR imaging for estimating intraosseous extent of osteosarcoma. AJR Am. J. Roentgenol. 167(5), 1211-1215 (1996).
96. Kim MS, Lee SY, Cho WH et al. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann. Surg. Oncol. 15(3), 906-914 (2008).
97. Dyke JP, Panicek DM, Healey JH et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 228(1), 271-278 (2003).
98. Soderlund V, Larsson SA, Bauer HC et al. Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur. J. Nucl. Med. 24(5), 511-515 (1997).
99. Cheon GJ, Kim MS, Lee JA et al. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J. Nucl. Med. 50(9), 1435-1440 (2009).
100. Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]- fluorodeoxy-d-glucose positron emission tomography. Cancer 94(12), 3277-3284 (2002).
101. Franzius C, Bielack S, Flege S et al. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J. Nucl. Med. 43(8), 1012-1017 (2002).
102. Bacci G, Ferrari S, Delepine N et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J. Clin. Oncol. 16(2), 658-663 (1998).
103. Bacci G, Ferrari S, Bertoni F et al. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy. Clin. Orthop. Relat. Res. 386, 186-196 (2001).
104. Bacci G, Loro L, Longhi A et al. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Anticancer Drugs 17(4), 411-415 (2006).
105. Schwartz CL, Gorlick R, Teot L et al. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J. Clin. Oncol. 25(15), 2057-2062 (2007).
106. Baldini N, Scotlandi K, Barbanti-Brodano G et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 333(21), 1380-1385 (1995).
107. Gorlick R, Huvos AG, Heller G et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. 17(9), 2781-2788 (1999).
108. Ifergan I, Meller I, Issakov J, Assaraf YG. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer 98(9), 1958-1966 (2003).
109. Man TK, Chintagumpala M, Visvanathan J et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 65(18), 8142-8150 (2005).
110. Lee JA, Kim MS, Kim DH et al. Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma. Pediatr. Blood Cancer 52(3), 340-345 (2009).
111. Bacci G, Ferrari S, Forni C et al. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute. Chir. Organi Mov. 81(4), 369-382 (1996).
112. Wilkins RM, Cullen JW, Camozzi AB, Jamroz BA, Odom L. Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity. Clin. Orthop. Relat. Res. 438, 128-136 (2005).
113. Tsuchiya H, Tomita K, Mori Y et al. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res. 18(1B), 657-666 (1998).
114. Lewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized Phase III trial of the European Osteosarcoma Intergroup. J. Natl Cancer Inst. 99(2), 112-128 (2007)
115. Lawrence JA, Babyn PS, Chan HS et al. Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology 189(1), 43-47 (1993).
116. Holscher HC, Bloem JL, Vanel D et al. Osteosarcoma: chemotherapy-induced changes at MR imaging. Radiology 182(3), 839-844 (1992).
117. Shin KH, Moon SH, Suh JS, Yang WI. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin. Orthop. Relat. Res. 376, 200-208 (2000).
118. Kim MS, Lee SY, Cho WH et al. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response. J. Orthop. Sci. 14(3), 292-297 (2009).
119. Briccoli A, Rocca M, Salone M et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 104(8), 1721-1725 (2005).
120. Grimer RJ, Sommerville S, Warnock D et al. Management and outcome after local recurrence of osteosarcoma. Eur. J. Cancer 41(4), 578-583 (2005).
121. Bacci G, Forni C, Longhi A et al. Local recurrence and local control of nonmetastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J. Surg. Oncol. 96(2), 118-123 (2007).
122. Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J. Pediatr. Hematol. Oncol. 25(11), 840-841 (2003).